Date | Price Target | Rating | Analyst |
---|---|---|---|
7/22/2022 | $7.00 | Overweight | Cantor Fitzgerald |
11/30/2021 | $50.00 → $27.00 | Buy | B. Riley Securities |
4 - BIOVIE INC. (0001580149) (Issuer)
4 - BIOVIE INC. (0001580149) (Issuer)
4 - BIOVIE INC. (0001580149) (Issuer)
4 - BIOVIE INC. (0001580149) (Issuer)
4 - BIOVIE INC. (0001580149) (Issuer)
Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim's impact on neurological symptoms associated with long COVID Key milestone reached ahead of schedule, with BioVie on track to receive additional $12.6 million of award from the U.S. Department of Defense and initiate the Phase 2 trial Recent Centers for Disease Control and Prevention survey estimated over 5% of U.S. adults currently have long COVID, and ~3.6 million people reported significantly modifying their activities because of illness1 CARSON CITY, Nev., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage co
Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim experienced 2 to 4 years age deceleration advantage compared to placebo Bezisterim modulated DNA methylation of proinflammatory genes and appeared to promote the transition of M1 proinflammatory to M2 anti-inflammatory macrophages Bezisterim was associated with 1.5 to 2.3 "fold enrichment" on gene control for hundreds of genes in pathways associated with neurodegenerative disorders and biological processes CARSON CITY, Nev., Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage compa
CARSON CITY, Nev., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster presentation will be shared at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) being held August 26-30, 2024 in Copenhagen, Denmark. The presentation "Bezisterim Effects on Biological Age, Alzheimer's Epigenetics, and Neurologic Assessments" will provide an overview of clinical data to-date on bezisterim, focusing on various analyses and measurements related to longevity and it
Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim's impact on neurological symptoms associated with long COVID Key milestone reached ahead of schedule, with BioVie on track to receive additional $12.6 million of award from the U.S. Department of Defense and initiate the Phase 2 trial Recent Centers for Disease Control and Prevention survey estimated over 5% of U.S. adults currently have long COVID, and ~3.6 million people reported significantly modifying their activities because of illness1 CARSON CITY, Nev., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage co
Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim experienced 2 to 4 years age deceleration advantage compared to placebo Bezisterim modulated DNA methylation of proinflammatory genes and appeared to promote the transition of M1 proinflammatory to M2 anti-inflammatory macrophages Bezisterim was associated with 1.5 to 2.3 "fold enrichment" on gene control for hundreds of genes in pathways associated with neurodegenerative disorders and biological processes CARSON CITY, Nev., Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage compa
CARSON CITY, Nev., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster presentation will be shared at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) being held August 26-30, 2024 in Copenhagen, Denmark. The presentation "Bezisterim Effects on Biological Age, Alzheimer's Epigenetics, and Neurologic Assessments" will provide an overview of clinical data to-date on bezisterim, focusing on various analyses and measurements related to longevity and it
CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or
RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (
Includes Pivotal Phase 3 Alzheimer's Asset NE3107 Cuong V. Do Named CEO of The New BioVie Conference Call Scheduled for April 27, 2021 at 5:00PM EDT SANTA MONICA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced the acquisition of the biopharmaceutical assets of NeurMedix, Inc., (NeurMedix), a San Diego based privately held clinical-stage pharmaceutical company focused on novel therapeutic assets for the treatment of neurodegenerative and neurological disorders, as well as certain cancers. Under the terms of the agreeme
ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopaAdditional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson's disease that helped inform SUNRISE-PD trial design CARSON CITY, Nev., June 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from two presentations at the Advanced Therapeutics in Movement and Related Disorders Con
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00
B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously
SC 13D/A - BIOVIE INC. (0001580149) (Subject)
SC 13D/A - BIOVIE INC. (0001580149) (Subject)
SC 13D/A - BIOVIE INC. (0001580149) (Subject)
8-K - BIOVIE INC. (0001580149) (Filer)
8-K/A - BIOVIE INC. (0001580149) (Filer)
8-K - BIOVIE INC. (0001580149) (Filer)